OAM
CTKB icon

Oxford Asset Management’s Cytek Biosciences CTKB Stock Holding History

Oxford Asset Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-37,509
Closed -$130K – 548
2025
Q3 		$130K Buy
37,509
+24,836
+196% +$93.2K 0.04% 394
2025
Q2 		$43.1K Sell
12,673
-13,967
-52% -$46.5K 0.01% 500
2025
Q1 		$107K Buy
+26,640
New +$138K 0.05% 419
2024
Q4 		– Sell
-25,257
Closed -$140K – 486
2024
Q3 		$140K Buy
+25,257
New +$143K 0.12% 266
2024
Q2 		– Sell
-13,726
Closed -$92.1K – 313
2024
Q1 		$92.1K Buy
+13,726
New +$109K 0.1% 228

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Oxford Asset Management's CTKB Position: Q4 2025 in Review

Oxford Asset Management sold out of Cytek Biosciences (CTKB) in Q4 2025, closing a stake of 37,509 shares — an estimated $130K sold.

Oxford Asset Management first reported a position in CTKB in Q1 2024 and held it in 5 quarters. The position peaked at $140K in Q3 2024. 155 funds tracked by Wall St. Rank hold CTKB as of Q4 2025.

  • Oxford Asset Management reported no remaining Cytek Biosciences position as of Q4 2025 after selling out during the quarter.
  • Oxford Asset Management sold 37,509 Cytek Biosciences shares in Q4 2025, an estimated $130K.
  • Oxford Asset Management first reported a position in Cytek Biosciences in Q1 2024 and held it in 5 quarters.
  • Oxford Asset Management's Cytek Biosciences position peaked at $140K in Q3 2024.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2025.

Based on Oxford Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.